Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Racial disparities in mycosis fungoides - from self-reported race to genetic ancestry analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CVCésar A. VirgenMPMelissa PulitzerSHSarah McCue Horwitz

Discussion

Loading...

Member takes

Overview

Analysis reveals racial disparities in clinical characteristics and outcomes in mycosis fungoides and Sezary syndrome patients, highlighting the role of genetic ancestry.

Key Points

  • To investigate the influence of genetic ancestry on racial disparities in mycosis fungoides and Sezary syndrome.
  • Compared clinical characteristics of patients by self-reported race and genetic ancestry.
  • Used MSK-IMPACT for genetic profiling.
  • Inferred genetic ancestry with ADMIXTURE and SNP data.
  • AFR patients diagnosed 10 years younger than EUR/ASJ patients (p=0.01).
  • AFR patients presented with stage IA disease less frequently than EUR/ASJ (0% vs 23.2%, p=0.01).
  • Trends indicated higher disease-related mortality and worse progression-free survival in AFR patients.

Cite This Study

Virgen et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deb7https://doi.org/10.1182/blood-2025-5424
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Racial differences in survival and prognostic factors among patients with mycosis fungoides and Sézary syndrome: A systematic review and meta-analysis.2026
  2. 2Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries2025
  3. 3Genomic landscape of mycosis fungoides2025
  4. 4Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis2025
  5. 5Mutation landscape and pathway-level disparities in Black versus White patients with acute myeloid leukemia.2026